Samsung Bioepis launches Imraldi biosimilar in Europe
SEOUL, Oct. 17 (Yonhap) -- South Korean biopharmaceutical firm Samsung Bioepis Co. said Wednesday it has launched its biosimilar Imraldi in the European market.
Imraldi -- a copy of the autoimmune disease drug Humira -- will first be commercialized